Novartis (NVS) said Friday that a phase 3 trial evaluating Rhapsido (remibrutinib) met primary endpoints across the three most common chronic inducible urticaria subtypes.

Rhapsido showed higher complete response rates versus placebo across the three subtypes, including 29.3% vs 14% in symptomatic dermographism, 56.3% vs 14.6% in cold urticaria and 29.3% vs 15.8% in cholinergic urticaria, the company said.

The drug demonstrated a favorable safety profile with no observed liver safety concerns, Novartis said.

Rhapsido is under FDA review for the symptomatic dermographism subtype and additional submissions to health authorities globally are expected this year, the company said.